Indian flip-flop scars pioglitazone sales as competitors pounce
This article was originally published in Scrip
Executive Summary
India's recent regulatory flip-flop over concerns of the risk of bladder cancer appears to have scarred the diabetes drug, pioglitazone, eroding value of both the molecule and its combinations on the Indian market.